NasdaqCM:IMNMBiotechs
How Varegacestat Phase 3 Results and NDA Plans Could Shape Immunome’s (IMNM) Late-Stage Strategy
Immunome recently granted stock options to three new hires under its 2024 Inducement Plan and highlighted strong Phase 3 RINGSIDE data for its lead cancer drug candidate, varegacestat, while also scheduling a presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Together, the positive clinical results, upcoming New Drug Application plans for varegacestat, and new equity-based hiring incentives underscore Immunome’s efforts to build a pipeline and team around its late-stage...